Validate Biomarkers
Test exploratory signatures in independent, clinically characterized ALS samples using predefined assay criteria.
Precision Biomarker-Guided ALS Therapeutic Program
A biomarker-guided investigational approach in preclinical development.
One Program with a Defined Development Focus
The current program connects exploratory patient-selection biomarkers with an investigational combination approach and predefined evidence priorities.
- Program
- Precision Biomarker-Guided ALS Therapeutic Program
- Disease Focus
- Amyotrophic lateral sclerosis
- Approach
- Investigational combination targeting inflammatory pathways and redox balance
- Current Stage
- Preclinical development
- Evidence Priorities
- Biomarker validation, combination testing and translational study planning
Clinical safety and efficacy have not been established. Further studies are needed to inform future clinical development.
The Evidence Guiding Our Next Steps
Progress will depend on predefined evidence milestones.
Evaluate the Combination
Compare the investigational combination with individual components and simpler regimens. Assess biological response alongside functional outcomes.
Plan Translation
Develop dose, exposure and safety study plans. Use the findings to inform a future regulatory and clinical development strategy.